Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Larry, Alphs"'
Autor:
Alexander Keenan, Yvonne Kayiteshonga, Larry Alphs, Ibrahim Turkoz, Virginia Smith-Swintosky, Emily Abraham, Alain Schotte, Eileen Hooker, Jean Damascene Iyamuremye, Rutakayile Bizoza, Branislav Mancevski
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Objective To evaluate the feasibility of conducting a large clinical trial within the Rwandan mental healthcare system that would establish the safety, efficacy and benefit of paliperidone palmitate once-monthly (PP1M) and once-every-3-months (PP3M)
Externí odkaz:
https://doaj.org/article/ea1cdb21811f495eba1fdcec76dcc478
Autor:
David J. Williamson, Keith H. Nuechterlein, Todd Tishler, Joseph Ventura, Benjamin M. Ellingson, Ibrahim Turkoz, Richard S.E. Keefe, Larry Alphs
Publikováno v:
Schizophrenia Research: Cognition, Vol 30, Iss , Pp 100270- (2022)
Objective: Persons with schizophrenia exhibit greater neurocognitive test score dispersion. Here, we seek to characterize dispersion on the Neurocognitive Composite subtests of the Measurement of Treatment Research to Improve Cognition in Schizophren
Externí odkaz:
https://doaj.org/article/19df96c5526c40fd9d7ef4b01200ce4e
Autor:
Larry, Alphs, Pamela, Baker, Brianne, Brown, Dong-Jing, Fu, Ibrahim, Turkoz, Keith H, Nuechterlein
Publikováno v:
Schizophrenia Research. 248:58-63
A post hoc analysis of the Disease Recovery Evaluation and Modification (DREaM) study was conducted to evaluate time to first major treatment failure (ie, arrest/incarceration or psychiatric hospitalization) in participants with recent-onset schizoph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3316b0653bb87a7afa42e2ef9057773a
https://doi.org/10.1016/j.schres.2022.07.015
https://doi.org/10.1016/j.schres.2022.07.015
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0220763 (2019)
BackgroundMany patients with major depressive disorder (MDD) fail to respond to antidepressant (AD) pharmacotherapy. The objectives of this study were to characterize MDD and treatment-resistant depression (TRD) at the level of pharmacologically trea
Externí odkaz:
https://doaj.org/article/725f70e291a84d19a986aec794b77c1e
Autor:
David G Daniel, Alex S Cohen, Dawn Velligan, Phillip D Harvey, Larry Alphs, Michael Davidson, William Potter, Alan Kott, Nina Schooler, Christopher R Brodie, Raeanne C Moore, Pierre Lindenmeyer, Stephen R Marder
Publikováno v:
Schizophrenia Bulletin Open. 4
In contrast to the validated scales for face-to-face assessment of negative symptoms, no widely accepted tools currently exist for remote monitoring of negative symptoms. Remote assessment of negative symptoms can be broadly divided into 3 categories
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eeca160c471035d50bb9ef59987a016a
https://doi.org/10.1093/schizbullopen/sgad001
https://doi.org/10.1093/schizbullopen/sgad001
Autor:
Larry, Alphs, Dong-Jing, Fu, David, Williamson, Carol, Jamieson, John, Greist, Magdalena, Harrington, Jean-Pierre, Lindenmayer, Cheryl, McCullumsmith, David V, Sheehan, Richard C, Shelton, Paul, Wicks, Carla M, Canuso
Publikováno v:
Innov Clin Neurosci
OBJECTIVE: Most assessments of suicidal ideation and behavior (SIB) are limited by reliance on a single assessor, typically a clinician or patient, with scant detail on patient-related drivers of SIB and inability to detect rapid change in SIB. Furth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dedc6cb3e7dd6bb06366b790bc837d06
https://pubmed.ncbi.nlm.nih.gov/35958973
https://pubmed.ncbi.nlm.nih.gov/35958973
Autor:
Larry Alphs, Ibrahim Turkoz, Virginia Smith-Swintosky, Alexander Keenan, Emily Abraham, Alain Schotte, Eileen Hooker, Jean Damascene Iyamuremye, Yvonne Kayiteshonga, Rutakayile Bizoza, Branislav Mancevski
Publikováno v:
BMJ Open. 13:e064675
ObjectiveTo evaluate the feasibility of conducting a large clinical trial within the Rwandan mental healthcare system that would establish the safety, efficacy and benefit of paliperidone palmitate once-monthly (PP1M) and once-every-3-months (PP3M) l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdf815c917881c77ef2203bc3e1ec158
https://doi.org/10.1136/bmjopen-2022-064675
https://doi.org/10.1136/bmjopen-2022-064675
Publikováno v:
Neuropsychiatric Disease and Treatment
Carmela Benson,1 David Singer,2 Colleen M Carpinella,3 May Shawi,4 Larry Alphs4 1Real-World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2293245e102a0a36f17e513a7645b4ef
http://europepmc.org/articles/PMC7822234
http://europepmc.org/articles/PMC7822234
Publikováno v:
The American Journal of Geriatric Psychiatry. 28:350-362
To compare the clinical and economic burden of treatment-resistant depression (TRD) among older adult patients with major depressive disorder (MDD) to non-TRD MDD and non-MDD patients.Retrospective cohort study using 5% Medicare data (January 1, 2012
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15dea2c50889f28daf95da3997a0afd6
https://doi.org/10.1016/j.jagp.2019.10.012
https://doi.org/10.1016/j.jagp.2019.10.012
Publikováno v:
European Neuropsychopharmacology. 29:1433-1441
This study examined the clinical utility of the Negative Symptom Assessment-16 (NSA-16) in schizophrenia. 274 individuals with schizophrenia were assessed on the NSA-16, Positive and Negative Syndrome Scale (PANSS), Clinical Assessment for Negative S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e821cf213f6af16d8fa104b9c65f1eea
https://doi.org/10.1016/j.euroneuro.2019.10.009
https://doi.org/10.1016/j.euroneuro.2019.10.009